Blog

Alnylam sets ambitious goal: Be among top 5 most-valuable biotechs by 2025

johnmaraganore-candid-300dpi900xx1350-900-84-0

The Cambridge drugmaker’s announcement carries on a history of making headlines the day before the industry’s largest annual conference.

Read More